NEWARK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ: DEPO ) announced today the presentation of ten abstracts at PAINWeek ® 2016, the nation's largest annual meeting for frontline clinicians in the area of pain management being held September 6 -10, 2016 in Las Vegas. The abstracts will highlight data from studies of Nucynta ER ® (tapentadol), as well as cebranopadol, a novel first-in-class investigational medicine, both designed to target multiple sources of pain - nociceptive and neuropathic. Depomed will be also presenting data from a study of Gralise ® (gabapentin), approved for pain caused by shingles.
The abstracts will be presented as posters beginning on the morning of Thursday, September 8, at the Scientific Session and Reception with author-led presentations from 6:30pm – 8:30pm.
NUCYNTA ER
Posters #42 and #43 – describe studies of NUCYNTA ER conducted by the Rocky Mountain Poison & Drug Center analyzing data compiled from the Researched Abuse, Diversion and Addiction-Related Surveillance System (RADARS ® ) Poison Center Program
Gralise
Poster #116 – “Comparison of Pharmacokinetics and Simulated Driving Performance Healthy Volunteers Taking Therapeutic Doses of Gastroretentive Gabapentin, Gabapentin, or Pregabalin”
Lazanda ®
Poster #115 – "Updated and Validated Comparison of Plasma and Cerebrospinal Fluid Fentanyl Pharmacokinetics and Bioavailability When Delivered Intranasally or Sublingually"
Cebranopadol
Poster #19 - “Cebranopadol, a Novel First-in-class Analgesic: Results from a Study in Patients with Moderate to Severe Pain Following Bunionectomy”
Poster #23 – “Cebranopadol, A Novel First-in-class Analgesic: Efficacy, Safety, Tolerability in Patients With Mixed Chronic Low Back Pain”
Poster #36 - “Cebranopadol: A Novel First-in-class Analgesic: Efficacy, Safety, Tolerability in Patients With Pain Due to Diabetic Peripheral Neuropathy”
Poster #67 - “Cebranopadol, a Novel First-in-class Analgesic: Optimization of the Up-titration Regimen to Individual Best Dose for Patients Suffering from Moderate to Severe Chronic Pain”
Poster #95 – “Cebranopadol: A Novel First-in-class Analgesic in Development For Chronic Pain Conditions - Results From a Human Abuse Potential Study in Non-dependent Recreational Opioid Users”
Poster #96 - “Cebranopadol: A Novel First-in-class Analgesic in Development for Chronic Pain Conditions - Effects on Respiration in Healthy Human Volunteers”
Depomed is pleased to be sponsoring the following events:
Product Theatres
NUCYNTA ER: "Targeting Success: An Interactive Discussion of a Next Generation Molecule" Date/Time: Wednesday, September 7, 2016 / 12:30pm – 1:30pm
Gralise: “Understanding Mechanism of Delivery in a Treatment for Postherpetic Neuralgia (PHN)” Date/Time: Thursday, September 8, 2016 / 12:30pm – 1:30pm
Continuing Medical Education (CME) Program
“Evolving Strategies for Chronic Pain Management: Targeting Multiple Pain Mechanisms to Improve Efficacy and Reduce Opioid Abuse Potential” Date/Time: Saturday, September 10, 2016 / 7:50am – 1:30pm
Thought-Leader Summit (Invitation-Only)
“New Perspectives in Management of Chronic Pain in the Primary Care Setting: Providing Relief While Preventing Abuse”
Depomed company representatives will be hosting conference attendees at its booth, #217 .
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com .
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 ckeenan@depomed.com
